Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Mesoblast's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEOBF vs VRTX, REGN, RVMD: Total Payout Ratio Comparison
For the Biotechnology subindustry, Mesoblast's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesoblast Total Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mesoblast's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Mesoblast's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mesoblast (MEOBF) has a Total Payout Ratio of 0.00 as of Aug. 03, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Mesoblast and its competitors.
Is Mesoblast's Total Payout Ratio too high?
Mesoblast's current Total Payout Ratio is 0.00. Overall, Mesoblast has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Total Payout Ratio compare to VRTX and REGN?
Mesoblast's Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Mesoblast and its competitors. Mesoblast's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Based on GuruFocus' analysis, Mesoblast (MEOBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.70 — trading 962.5% above its estimated fair value. The current Total Payout Ratio is 0.00. Mesoblast's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Mesoblast (MEOBF), the current Total Payout Ratio is 0.00 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mesoblast (MEOBF) Overvalued in 2026?
Based on GuruFocus' analysis, Mesoblast stock appears to be overvalued.
The current stock price of $1.70 is trading 962.5% above its estimated GF Value™ of $0.16.
GuruFocus considers Mesoblast to be Significantly Overvalued.
Key valuation signals for MEOBF:
Total Payout Ratio: 0.00
GF Value™: $0.16 vs. price of $1.70 (962.5% above fair value)
No single metric tells the full story. See the MEOBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
49GF Score
Get the complete analysis for MEOBF
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEOBF has been successfully added to your 
